Advik Laboratories Ltd

Meeting Details

• Date, time, venue: 02 Sep 2026, 3:00 PM, at 703, Arunachal Building, 19, Barakhambha Road, New Delhi-110001.

Key Agenda Items

• To consider and approve the AGM notice for FY 2025-26.
• To approve Director’s Report, MD&A and Corporate Governance Report for FY 2025-26.
• To fix date, time and venue of the forthcoming AGM for FY 2025-26.
• To appoint a Scrutinizer for the forthcoming AGM.
• To fix book-closure and E-voting dates and related matters.
• To consider any other matter with the permission of the Board.

Other Notes

• Company renamed as MPS Pharmaa Limited from Advik Laboratories Limited.

Financial results approved

• Standalone unaudited results for quarter ended 30 June 2026 approved.
• Limited Review Report on the standalone results approved.

Regulatory filings and outlook

• FDA licence renewal for drug manufacturing applied; under consideration.
• Management expects restart; pursuing market opportunities and new deal prospects.

Auditor remarks and emphasis

• Auditors' review notes no revenue from operations in quarter ended June 2026.
• Basis of qualified conclusion: investment fair value not determined; WIP stalled.

Market and regulatory actions

• BSE trading suspended for unpaid listing fees; weekly Trade-for-Trade allowed.
• March 31, 2026 figures are balancing figures.

Compliance status

• Dematerialisation requests were confirmed to depositories within 15 days.
• Security certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted in records within 15 days.
• Depository and stock exchanges where listed were updated within 15 days.
• Register of Members updated accordingly.

Investor complaints status

• Pending complaints at start of quarter: NIL.
• Complaints received during quarter: NIL.
• Complaints disposed of during quarter: NIL.
• Complaints unresolved at end of quarter: NIL.